Keyphrases
Parkinson's Disease
100%
Core Outcome Set
100%
Clinical Trials
73%
Sorafenib
50%
Risk Outcomes
50%
Patient Outcomes
50%
Risk-benefit
50%
Randomized Controlled Trial
50%
Patient Benefit
50%
Drug Development
50%
Patient Risk
50%
Trialists
38%
FDA-approved Drugs
21%
Off-label Indications
21%
Uptake Rate
16%
Adverse Events
14%
Approved Indication
14%
Monotherapy
14%
Objective Response Rate
14%
Trial Characteristics
12%
Data Extraction
12%
Disease Research
10%
Descriptive Statistics
9%
Inferential Statistics
9%
Overall Response Rate
7%
Differentiated Thyroid Carcinoma
7%
Excessive Risk
7%
Oncology Drugs
7%
New Indication
7%
Response Criteria
7%
Median Progression-free Survival
7%
Adverse Event Rates
7%
Bibliographic Databases
7%
Cancer Treatment
7%
Trends over Time
7%
Drug Trials
7%
Trial Participants
7%
Cancer Drugs
7%
Median Overall Survival
7%
Literature Search
7%
Clinical Endpoints
7%
Pharmaceutical Companies
7%
Admissions Outcomes
5%
Multiple Outcomes
5%
Post-core
5%
Measurement Instrument
5%
Clinical Outcomes
5%
Hospital Admission
5%
Increased Incidence
5%
Research Funding
5%
Medicine and Dentistry
Parkinson's Disease
100%
Clinical Trial
68%
Cross Sectional Study
50%
Sorafenib
50%
Randomized Controlled Trial
50%
Systematic Review
50%
Uptake Rates
30%
Adverse Event
21%
Parkinson's Disease Clinical Trial
20%
Malignant Neoplasm
14%
Monotherapy
14%
Post and Core
10%
Outcome Assessment
10%
Inferential Statistics
9%
Differentiated Thyroid Cancer
7%
Oncology
7%
Cancer Therapy
7%
Drug
7%
Drug Screening
7%
Overall Survival
7%
Progression Free Survival
7%